Rankings
▼
Calendar
EBS Q4 2016 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena
EBS
Emergent BioSolutions Inc.
$433M
Q4 2016 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$152M
Gross Profit
$86M
56.9% margin
Operating Income
$51M
33.6% margin
Net Income
$37M
24.7% margin
EPS (Diluted)
$0.67
QoQ Revenue Growth
+6.1%
Cash Flow
Operating Cash Flow
-$9M
Free Cash Flow
-$29M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$970M
Total Liabilities
$374M
Stockholders' Equity
$596M
Cash & Equivalents
$272M
← FY 2016
All Quarters
Q1 2017 →
